iShares Biotechnology ETF (IBB)
| Assets | $7.12B |
| Expense Ratio | 0.45% |
| PE Ratio | 16.40 |
| Shares Out | 55.55M |
| Dividend (ttm) | $0.41 |
| Dividend Yield | 0.33% |
| Ex-Dividend Date | Mar 21, 2024 |
| Payout Ratio | 5.34% |
| 1-Year Return | -3.36% |
| Volume | 2,008,718 |
| Open | 126.78 |
| Previous Close | 127.76 |
| Day's Range | 124.39 - 127.27 |
| 52-Week Low | 111.83 |
| 52-Week High | 141.16 |
| Beta | 0.83 |
| Holdings | 224 |
| Inception Date | Feb 5, 2001 |
About IBB
Fund Home PageThe iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.
Top 10 Holdings
51.42% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 8.65% |
| Vertex Pharmaceuticals Incorporated | VRTX | 8.26% |
| Regeneron Pharmaceuticals, Inc. | REGN | 8.14% |
| Gilead Sciences, Inc. | GILD | 8.07% |
| IQVIA Holdings Inc. | IQV | 4.57% |
| Moderna, Inc. | MRNA | 3.86% |
| Biogen Inc. | BIIB | 3.08% |
| Mettler-Toledo International Inc. | MTD | 2.76% |
| Illumina, Inc. | ILMN | 2.05% |
| argenx SE | ARGX | 1.99% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 21, 2024 | $0.12599 | Mar 27, 2024 |
| Dec 20, 2023 | $0.12396 | Dec 27, 2023 |
| Sep 26, 2023 | $0.15316 | Oct 2, 2023 |
| Jun 7, 2023 | $0.00621 | Jun 13, 2023 |
| Mar 23, 2023 | $0.06456 | Mar 29, 2023 |
| Dec 13, 2022 | $0.1014 | Dec 19, 2022 |
News
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Biotech's Next Gold Rush: Weight-Loss Drugs
Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.
Navigating the big run in biotech
The 'Halftime Report' Investment Committee debates the upside potential in the biotech space.
Health care's underperformance last year sets it up well for 2024, says Mara Goldstein
Mara Goldstein, Biotech Analyst at Mizuho, discusses health care's outperformance this week.
Dr. Scott Gottlieb talks Big Pharma's buying spree
Dr. Scott Gottlieb, joins 'Closing Bell' to discuss the government's regulation on the pharmaceutical industry.
Wedbush's Laura Chico talks biotech investing in 2024
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
Buy or bail on biotech: Here's what you need to know
Biotech is up double digits this month. Piper Sandler says that the sector is breaking out.
Biotech Stocks Are Breaking Out—and They Show No Sign of Slowing Down
Shares have gotten a boost from the Fed and from M&A.
Wells Fargo's top pharma picks for 2024
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
We see Big Pharma going after smaller biotechs in 2024, says Jefferies' Michael Yee
Michael Yee, Jefferies senior biotech analyst, joins 'Squawk Box' to discuss the state of the biotech industry, impact of interest rate environment on the sector, growth outlook in 2024, obesity drug ...
How to Find the Best Biotech ETFs
The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.
Goldman Sachs' Chris Shibutani talks his top biotech picks including Eli Lilly and Pfizer
Chris Shibutani, Goldman Sachs Senior Analyst, joins 'Closing Bell Overtime' to talk his top picks in the biotech sectors.
Final Trades: Abbvie, Thermo Fisher & more
The "Halftime Report" traders give their top picks to watch for the second half.
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.
SVB fallout: The impacts on the biotech sector
CNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.
The Recent Bullish Trend in IBB, XBI Looks Shaky
Rising interest rates taking steam from rally that powered in IBB and XBI.
Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data
Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors m...
Pharmaceutical companies losing patent protection as competition grows
The Wall Street Journal's Jared Hopkins joins 'Power Lunch' to discuss biotech patent protection duration, competition coming to the pharmaceutical industry and pharmaceutical M&A plans.
There's a crop of great biotech companies ready to be acquired, says MPM's Christiana Bardon
Dr. Christiana Bardon, co-managing partner of MPM's BioImpact Capital, joins 'The Exchange' to discuss tailwinds in the pharmaceutical and biotech sector, innovation in obesity drugs, and acquisition ...
Why Biotech Is Poised for a Recovery This Year
Pharma and biotech stocks moved in opposite directions last year, but fortunes are shifting.
Subversive Launches ETF to Focus on Mental Health
The debut highlights the lack of funds focused on the area.
JPMorgan's bullish call on biopharma
The "Halftime Report" traders debate the biggest analyst calls of the day.
Final Trades: IBB, META, TSM & LVS
The traders make their final trades of the week. With CNBC's Dominic Chu and the Fast Money traders, Tim Seymour, Courtney Garcia, Steve Grasso and Jeff Mills.
ETFs Find a Role in a Long-Term Portfolio
Albion Financial's Jason Ware sees funds as mainstays in ‘core-satellite' planning.
We still think there's more room for biotech to go higher, says Jefferies' Yee
Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late ...